Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-19,900
Closed -$1.94M 4562
2025
Q3
$1.94M Sell
19,900
-5,800
-23% -$467K ﹤0.01% 3004
2025
Q2
$1.79M Sell
25,700
-32,700
-56% -$1.87M ﹤0.01% 2822
2025
Q1
$2.9M Sell
58,400
-20,000
-26% -$1.26M ﹤0.01% 2327
2024
Q4
$5.48M Buy
78,400
+55,100
+236% +$4.58M ﹤0.01% 1903
2024
Q3
$2.44M Buy
23,300
+10,300
+79% +$1.2M ﹤0.01% 2558
2024
Q2
$1.85M Sell
13,000
-10,000
-43% -$1.15M ﹤0.01% 2720
2024
Q1
$2.56M Sell
23,000
-11,100
-33% -$1.32M ﹤0.01% 2435
2023
Q4
$4.42M Sell
34,100
-6,900
-17% -$951K ﹤0.01% 2008
2023
Q3
$6.69M Buy
41,000
+19,900
+94% +$3.5M 0.01% 1574
2023
Q2
$3.87M Buy
+21,100
New +$3.04M ﹤0.01% 2065

Other funds holding ACLS

David Shaw's ACLS Position: Q2 2026 in Review

David Shaw reduced its Axcelis (ACLS) stake by 76% in Q2 2026, selling an estimated $61M and leaving 133,044 shares worth $25.2M. The position accounts for 0.01% of the portfolio, ranked #1139.

David Shaw first reported a position in ACLS in Q2 2013 and has held it in 41 quarters since. The position peaked at $50.7M in Q1 2026. 439 funds tracked by Wall St. Rank hold ACLS as of Q2 2026.

  • David Shaw held 133,044 shares of Axcelis worth $25.2M as of Q2 2026.
  • David Shaw sold 411,377 Axcelis shares in Q2 2026, an estimated $61M.
  • Axcelis made up 0.01% of David Shaw's portfolio in Q2 2026, its #1139 holding.
  • David Shaw first reported a position in Axcelis in Q2 2013 and has held it in 41 quarters since.
  • David Shaw's Axcelis position peaked at $50.7M in Q1 2026.
  • 439 funds tracked by Wall St. Rank held Axcelis as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.